Nuwellis, Inc. annual report, FY2013

Business context and reporting period

This is Sunshine Heart, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, not a standalone fourth-quarter report. The filing names Sunshine Heart as the registrant; it does not identify Nuwellis, Inc. as the filer. Sunshine Heart was an early-stage medical-device company developing the C-Pulse heart-assist system for moderate-to-severe heart failure. The device was not approved for commercial sale in the United States; revenue came only from clinical-study implants.

Financial results and liquidity

Amounts below are in U.S. dollars; income-statement and cash-flow figures are for the year ended December 31.

Revenue remained immaterial, so operating margins are not meaningful as a measure of commercial performance. Research and development expense rose 68.7% to $13.50 million; selling, general and administrative expense rose 37.3% to $9.43 million. The company reported an income-tax benefit of $1.21 million, principally related to research-and-development tax credits. Cash and cash equivalents were $54.14 million at year-end, versus $14.22 million a year earlier; current assets were $54.64 million and current liabilities $3.50 million. Total liabilities were $3.50 million, with no borrowings shown on the balance sheet. Accumulated deficit was $101.01 million.

Material changes versus 2012

• Revenue increased from zero to $59,000, reflecting one clinical-study implant.
• Net loss widened by $7.69 million as operating expenses grew, particularly clinical and development spending and infrastructure costs.
• Cash increased by $39.91 million, mainly from $57.57 million of net proceeds from common-stock sales. Shares outstanding increased from 9.28 million to 16.83 million.
• Operating cash use increased by $4.28 million. The company remained dependent on external equity financing.

Outlook, commentary, risks and unusual items

• Enrollment in the 388-patient U.S. COUNTER HF pivotal study began in September 2013. Management expected enrollment to finish in 2016 and did not anticipate U.S. marketing before 2017.
• The C-Pulse system received CE Mark approval in July 2012. A European post-market study began enrolling in 2013; management expected enrollment completion by the end of 2014. The company had not obtained reimbursement in any European country and did not expect German reimbursement before 2015.
• Management expected research and development expense to remain above prior-year levels during 2014 and selling, general and administrative expense to remain elevated. It anticipated continued significant losses.
• The independent auditor reported substantial doubt about the company’s ability to continue as a going concern, citing recurring operating losses and projected capital needs. Management said continued operations depended on raising additional capital and successfully developing and commercializing the product.
• Key risks include pivotal-trial enrollment, safety and efficacy outcomes; FDA approval; reimbursement and market adoption; ongoing financing and potential dilution; and reliance on third-party suppliers. The specialized system balloon came from a single supplier.
• Feasibility-study data showed improvements in reported quality-of-life, NYHA class and walking measures, but were based on small patient groups. Reported device-related events included one aortic disruption and eight drive-line exit-site infections; the filing also describes deaths and device removals among study participants.
• In 2013, the company adopted a stockholder rights plan, issued shares in public offerings, and entered into an agreement allowing Aspire Capital to purchase up to $25 million of stock, subject to contractual limits.

Investor facts to verify

• Confirm the issuer and period: this source is Sunshine Heart’s FY2013 10-K, not a standalone Q4 filing or a filing under the Nuwellis name.
• Review subsequent financing, cash runway and dilution, given the going-concern qualification and continued operating cash burn.
• Track COUNTER HF enrollment, trial endpoints, adverse events and the timing and requirements for FDA review.
• Verify progress toward European reimbursement and any resulting commercial revenue; CE Mark approval alone did not establish reimbursement.
• Assess whether supplier concentration, particularly the single-source balloon, has changed and whether manufacturing can scale.